Cb mig q fod h rwczov l3d3dy5jb250 y wdpb25sa x zl lm nvb s92a wv3 l3 nlci0x m dktc2lnbmlma w nhbn rse s1pb x byb3 zl zc1xd w fsa xr5 lw9m l wxp zm ut zm9y lx jl y3 vycm vud c1jb g9zd h jp z glva w rlcy1ka w zma w npb g utc gf0a w vud hpsaqa
C Diff Drug Development
MTIG on Twitter
.@VedantaBio is developing oral drugs that are designed to deliver defined bacterial consortia to treat diseases linked to the #microbiome including #CDiff & #IBD. A Phase 3 trial of Vedanta’s VE303 for the treatment of #rCdiff is planned to begin in 2023. https://t.co/Xyew5il3Ba— MTIG (@MTIG_News) January 31, 2023
Abhishek Deshpande on Twitter
Happy to share our work in @JAMANetworkOpen In our study patients treated with SER-109 (an oral microbiome therapeutic) had significantly greater improvements in disease-specific HRQOL scores compared with patients treated with placebo through 8 wks #cdiff https://t.co/zL1iUg3LBz pic.twitter.com/77wCrrTIlv— Abhishek Deshpande (@abhishek_dp) January 30, 2023
Clostridium Difficile Infections Market Drugs are expected to get launched during the study period 2019-2032 | Major Companies- Merck, Optimer Pharmaceuticals (Acquired by Cubist Pharmaceuticals, Inc.), and others.
Design of 8-mer Peptides that Block Clostridioides difficile Toxin A in Intestinal Cells - PubMed
Infections by Clostridioides difficile , a bacterium that targets the large intestine (colon), impact a significant number of people worldwide. Bacterial colonization is mediated by two exotoxins: toxins A and B. Short peptides that can inhibit the biocatalytic activity of these toxins repres …
ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis - PubMed
Clostridioides difficile infection (CDI) causes intestinal injury. Toxin A and toxin B cause intestinal injury by inducing colonic epithelial cell apoptosis. ADS024 is a Bacillus velezensis strain in development as a single-strain live biotherapeutic product (SS-LBP) to prevent the rec …
Global Microbiome Therapeutics Market 2023: United States Projected to be the Dominant Regional Market | PMR
Gut Punch: Finch’s Flagging Microbiome Program Folds, Leading to 95% Staff Cut - MedCity News
Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.
Pharming the Microbiome
The gut microbiome plays a critical but poorly understood role in how drugs work or don't work in the body. It also presents therapeutic possibilities unto itself.
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets | MarketScreener
SOMERVILLE, Mass., Jan. 24, 2023 -- Finch Therapeutics Group, Inc. today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection and focus on... | January 24, 2023
MTIG on Twitter
.@ServatusLtd's drug development platforms contain engineered proteins for the treatment of autoimmune diseases and live biotherapeutics (LBPs) for the treatment of inflammatory conditions and bacterial infections including #IBD, #CDiff and H. pylori. https://t.co/eUgiukdHkL— MTIG (@MTIG_News) January 23, 2023
Antibacterial Activity of Crocus sativus L. Petals Extracts against Foodborne Pathogenic and Spoilage Microorganisms, with a Special Focus on Clostridia - PubMed
In recent years, there has been a growing interest in the use of novel antimicrobial agents able to inhibit or kill food-borne bacteria or to interrupt the onset of food spoilage. Crocus sativus L. petals, typically considered as waste obtained from saffron spice production, could be a source …
Clostridium Difficile Infections Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Rebiotix, Seres Therapeutics/ Aimmune, Summit Therapeutics, Mikrobiomik Healthcare
Clostridium Difficile Infection Treatment Market Next Big Thing | Merck, Baxter International, Sanofi
A Big Leap for Microbiome Therapeutics
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease | MarketScreener
MELBOURNE, Australia, Jan. 17, 2023 -- Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic... | January 17, 2023
Discovery of potential phytochemicals as inhibitors of TcdB, a major virulence factors of Clostridioides difficile - PubMed
Clostridioides difficile is a gram-positive bacterium which is associated with different gastrointestinal related infections, and the numbers of cases related to it are continuously increasing in the past few years. Owing to high prevalence and development of resistance towards available anti …
An Exciting Time in CDI: Approvals, Approaches and Anticipation
The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.
Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model - PubMed
Human body can digest only a few sugars with a low degree of polymerization. The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health. Adlay is a medicinal and food homologous crop. The study aims to determine whether de …
Research seeking to outsmart C. diff achieves sustained 50% decrease in infections across eight hospitals
According to recent research conducted at several member hospitals that are part of Trinity Health and published in Infection Control and Hospital Epidemiology, optimized environmental cleaning is the key to effectively reducing C. diff transmission inside hospitals.
Nifty new tools for microbiome treatment design
Nature Reviews Gastroenterology & Hepatology - The gut microbiome field is shifting from association to modulation. Microbiota-based treatments come in many shapes and sizes, ranging from...
Systematic Design of Adenosine Analogs as Inhibitors of a Clostridioides difficile-Specific DNA Adenine Methyltransferase Required for Normal Sporulation and Persistence
Antivirulence agents targeting endospore-transmitted Clostridioides difficile infections are urgently needed. C. difficile-specific DNA adenine methyltransferase (CamA) is required for efficient sporulation and affects persistence in the colon. The active site of CamA is conserved and …
Treatment efficacy of fecal microbiota-based live biotherapeutics (RBX2660) for the prevention of recurring Clostridioides difficile infection
Treatment efficacy of fecal microbiota-based live biotherapeutics (RBX2660) for the prevention of recurring Clostridioides difficile infection
Reaction to the Historic Approval of RBX2660
RBX2660 is the first ever live microbiota therapeutic approved by the FDA.
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Infectious Diseases and Therapy on Twitter
Read the final report from the phase 2b PUNCH CD2 study of RBX2660, an investigational live biotherapeutic to reduce C. difficile infection recurrence, showing 24-month safety and meaningful efficacy for 1 dose v placebo - https://t.co/hyVJ0cABVR#cdiff #microbiome— Infectious Diseases and Therapy (@InfectDis_Ther) December 22, 2022
An insight into the Clostridioides difficile infection-related diarrhea - PubMed
An insight into the Clostridioides difficile infection-related diarrhea
Antimicrobial Activity of Tannic Acid In Vitro and Its Protective Effect on Mice against Clostridioides difficile - PubMed
Clostridioides difficile infection (CDI), recurrently reported as an urgent threat owing to its increased prevalence and mortality, has attracted significant attention. As the use of antibiotics to treat CDI has many limitations, such as high recurrence rate, the need to actively seek and develop ot …
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection - PubMed
ClinicalTrials.gov: NCT02299570.
Global Microbiome Therapeutics Market Report 2022 - Players Include Evelo Biosciences, Ferring International, Immuron and LNC Therapeutics
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Microbiome